Form 4: Fulgent Genetics CFO Acquires Shares

Fulgent Genetics CFO and Treasurer, Paul Kim, acquired 2,747 shares of common stock on April 26, 2026, through a tax withholding transaction.

Summary

• Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc., acquired 2,747 shares of common stock on April 26, 2026.
• The acquisition was a result of shares being withheld to cover tax obligations arising from the vesting of restricted stock units.
• These restricted stock units were assumed under an Agreement and Plan of Merger dated November 7, 2022.
• Following this transaction, Paul Kim beneficially owns 365,800 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard tax-related share withholding rather than a discretionary purchase or sale by an insider.

Positives

• The CFO and Treasurer has acquired additional shares, indicating continued investment in the company.
• The transaction is a standard procedure for covering tax liabilities on vested equity awards, suggesting normal operational processes.

Negatives

• The acquisition represents shares withheld for tax purposes, not a direct purchase by the executive, which could be interpreted as a less enthusiastic investment signal.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of shares by a key executive like the CFO, even if for tax withholding, is a routine event that provides transparency into executive compensation and ownership.

Stakeholder Impact

• Shareholders: Increased transparency regarding executive compensation and share ownership. The transaction itself does not directly impact share count or market dynamics significantly.

Key Dates

Keywords

Fulgent Genetics, FLGT, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, Tax Withholding, Paul Kim, CFO, SEC Filing